Pharmacotherapy of alcohol dependence

L. Mohan, P. R. Shankar, P. Raut, S. Gyawali

Research output: Contribution to journalReview article

Abstract

Alcohol is a commonly used psychoactive substance all over the world and responsible for a significant proportion of mortality and morbidity. The treatment of alcohol dependence consists of two phases, detoxification and rehabilitation. Pharmacotherapy is being investigated to enhance abstinence and prevent relapse and complement interventions at a psychosocial level. Alcohol activates dopamine in the nucleus accumbens and mediates positive reinforcement and reward. The US Food and Drug Administration (FDA) have approved three medications, disulfiram, naltrexone and acamprosate for the treatment of alcohol dependence. The selective serotonin reuptake inhibitors (SSRIs) particularly fluoxetine and citalopram have been evaluated. Buspirone and Ondansetron have also been tried for alcohol dependence. Combination of naltrexone and acamprosate has shown promising results. It is essential to develop clinically useful pharmacological treatments, which can be evaluated using large-scale clinical trials. Clinical trial methodologies to evaluate combination treatments and using medications along with psychosocial treatments are required.

Original languageEnglish
Pages (from-to)2947-2955
Number of pages9
JournalJournal of Clinical and Diagnostic Research
Volume4
Issue number4
Publication statusPublished - 06-10-2010
Externally publishedYes

Fingerprint

Drug therapy
Alcoholism
Alcohols
Drug Therapy
Naltrexone
Clinical Trials
Buspirone
Therapeutics
Disulfiram
Ondansetron
Detoxification
Citalopram
Fluoxetine
Nucleus Accumbens
Serotonin Uptake Inhibitors
United States Food and Drug Administration
Reward
Patient rehabilitation
Dopamine
Reinforcement

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Clinical Biochemistry

Cite this

Mohan, L., Shankar, P. R., Raut, P., & Gyawali, S. (2010). Pharmacotherapy of alcohol dependence. Journal of Clinical and Diagnostic Research, 4(4), 2947-2955.
Mohan, L. ; Shankar, P. R. ; Raut, P. ; Gyawali, S. / Pharmacotherapy of alcohol dependence. In: Journal of Clinical and Diagnostic Research. 2010 ; Vol. 4, No. 4. pp. 2947-2955.
@article{8f256cd5db5a482baa6dd93ada4c19e5,
title = "Pharmacotherapy of alcohol dependence",
abstract = "Alcohol is a commonly used psychoactive substance all over the world and responsible for a significant proportion of mortality and morbidity. The treatment of alcohol dependence consists of two phases, detoxification and rehabilitation. Pharmacotherapy is being investigated to enhance abstinence and prevent relapse and complement interventions at a psychosocial level. Alcohol activates dopamine in the nucleus accumbens and mediates positive reinforcement and reward. The US Food and Drug Administration (FDA) have approved three medications, disulfiram, naltrexone and acamprosate for the treatment of alcohol dependence. The selective serotonin reuptake inhibitors (SSRIs) particularly fluoxetine and citalopram have been evaluated. Buspirone and Ondansetron have also been tried for alcohol dependence. Combination of naltrexone and acamprosate has shown promising results. It is essential to develop clinically useful pharmacological treatments, which can be evaluated using large-scale clinical trials. Clinical trial methodologies to evaluate combination treatments and using medications along with psychosocial treatments are required.",
author = "L. Mohan and Shankar, {P. R.} and P. Raut and S. Gyawali",
year = "2010",
month = "10",
day = "6",
language = "English",
volume = "4",
pages = "2947--2955",
journal = "Journal of Clinical and Diagnostic Research",
issn = "2249-782X",
publisher = "Journal of Clinical and Diagnostic Research",
number = "4",

}

Mohan, L, Shankar, PR, Raut, P & Gyawali, S 2010, 'Pharmacotherapy of alcohol dependence', Journal of Clinical and Diagnostic Research, vol. 4, no. 4, pp. 2947-2955.

Pharmacotherapy of alcohol dependence. / Mohan, L.; Shankar, P. R.; Raut, P.; Gyawali, S.

In: Journal of Clinical and Diagnostic Research, Vol. 4, No. 4, 06.10.2010, p. 2947-2955.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pharmacotherapy of alcohol dependence

AU - Mohan, L.

AU - Shankar, P. R.

AU - Raut, P.

AU - Gyawali, S.

PY - 2010/10/6

Y1 - 2010/10/6

N2 - Alcohol is a commonly used psychoactive substance all over the world and responsible for a significant proportion of mortality and morbidity. The treatment of alcohol dependence consists of two phases, detoxification and rehabilitation. Pharmacotherapy is being investigated to enhance abstinence and prevent relapse and complement interventions at a psychosocial level. Alcohol activates dopamine in the nucleus accumbens and mediates positive reinforcement and reward. The US Food and Drug Administration (FDA) have approved three medications, disulfiram, naltrexone and acamprosate for the treatment of alcohol dependence. The selective serotonin reuptake inhibitors (SSRIs) particularly fluoxetine and citalopram have been evaluated. Buspirone and Ondansetron have also been tried for alcohol dependence. Combination of naltrexone and acamprosate has shown promising results. It is essential to develop clinically useful pharmacological treatments, which can be evaluated using large-scale clinical trials. Clinical trial methodologies to evaluate combination treatments and using medications along with psychosocial treatments are required.

AB - Alcohol is a commonly used psychoactive substance all over the world and responsible for a significant proportion of mortality and morbidity. The treatment of alcohol dependence consists of two phases, detoxification and rehabilitation. Pharmacotherapy is being investigated to enhance abstinence and prevent relapse and complement interventions at a psychosocial level. Alcohol activates dopamine in the nucleus accumbens and mediates positive reinforcement and reward. The US Food and Drug Administration (FDA) have approved three medications, disulfiram, naltrexone and acamprosate for the treatment of alcohol dependence. The selective serotonin reuptake inhibitors (SSRIs) particularly fluoxetine and citalopram have been evaluated. Buspirone and Ondansetron have also been tried for alcohol dependence. Combination of naltrexone and acamprosate has shown promising results. It is essential to develop clinically useful pharmacological treatments, which can be evaluated using large-scale clinical trials. Clinical trial methodologies to evaluate combination treatments and using medications along with psychosocial treatments are required.

UR - http://www.scopus.com/inward/record.url?scp=77957288938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957288938&partnerID=8YFLogxK

M3 - Review article

VL - 4

SP - 2947

EP - 2955

JO - Journal of Clinical and Diagnostic Research

JF - Journal of Clinical and Diagnostic Research

SN - 2249-782X

IS - 4

ER -

Mohan L, Shankar PR, Raut P, Gyawali S. Pharmacotherapy of alcohol dependence. Journal of Clinical and Diagnostic Research. 2010 Oct 6;4(4):2947-2955.